Drug Information

Drug General Information
Drug ID
D06ZFV
Former ID
DIB006626
Drug Name
QPI-1007
Synonyms
SiCASP2; SiRNA therapy (caspase-2, ocular injury), Quark Pharmaceuticals
Drug Type
siRNA drug
Indication Glaucoma [ICD9: 365; ICD10:H40-H42] Phase 2/3 [525063]
Company
Quark pharmaceuticals
Target and Pathway
Target(s) mRNA of Caspase-2 Target Info [532894]
NetPath Pathway TCR Signaling Pathway
IL4 Signaling Pathway
Pathway Interaction Database HIV-1 Nef: Negative effector of Fas and TNF-alpha
Caspase Cascade in Apoptosis
Reactome NOD1/2 Signaling Pathway
NADE modulates death signalling
WikiPathways Apoptosis Modulation by HSP70
Apoptosis
Parkinsons Disease Pathway
Signalling by NGF
Apoptosis Modulation and Signaling
References
Ref 525063ClinicalTrials.gov (NCT02341560) Phase II/III, Randomized, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION). U.S. National Institutes of Health.
Ref 532894Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014 Aug;24(4):258-66.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.